BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Scripps Florida Scientist Launches Company, cuRNA


9/2/2008 7:28:04 AM

Claes Wahlestedt, who heads Scripps Florida’s efforts to develop drugs for diseases of the central nervous system, has launched new company with business consultant and longtime friend Joe Collard.

The company, which he has dubbed cuRNA, is developing a technology licensed from Scripps research that is based on the therapeutic potential of what are known as non-coding RNAs, or small molecules that once were thought of as little more than evolutionary leftovers.

However, as Wahlestedt and other scientists have discovered, these non-coding RNAs have been shown to play a vital role in gene expression, a process critical to a number of different disease states.

The technology licensed by Wahlestedt and Collards is broad-based and will take a lot of investment to develop commercially.

"Depending on the specific nature of the RNA involved, they can either elevate or suppress gene expression,” Wahlstedt said. “These things can be used in a number of important ways – to treat disease or as diagnostic markers or tools. All in all, they have some very significant therapeutic potential."

In the July issue of Nature Medicine, he showed for the first time how complicated the human genome is and how important the seemingly extraneous parts can be.

Wahlestedt has been with Scripps Florida since 2005. Prior to that, he was the founding director of the Center for Genomics and Bioinformatics at the Karolinska Institute in Stockholm, Sweden.

His company is the second spinoff for Scripps Florida. The first, Xcovery, was launched in 2006 by Scripps research scientist Chris Liang.

Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES